No trading signal. This is a routine compliance filing for share plan and dividend reinvestment. Monitor next quarterly results (2.02) or any material 8-K for actionable events.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 13 $52.29entry
- T+1 · 4mo ago −1.99%α −2.34% · $51.25
- T+5 · 4mo ago −1.01%α −0.23% · $51.76
- T+20 · 3mo ago −0.25%α −3.43% · $52.16
- T+60 · 6w ago −10.88%α −14.88% · $46.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK filed a routine 6-K reporting PDMR share acquisitions under the company's Share Reward Plan and dividend reinvestment on July 9, 2026. Multiple executives including the CEO, CFO, and other senior leaders acquired small numbers of ordinary shares at ~£19.63, with the largest single purchase being 1,050 shares by a PCA of the Company Secretary. This is a standard administrative disclosure with no material financial or strategic implications.
Key Facts
- CEO Luke Miels acquired 3 ordinary shares via dividend reinvestment at £19.6290.
- CFO Julie Brown acquired 12 ordinary shares (6 partnership + 6 matching) under the Share Reward Plan at £19.6290.
- Largest single transaction: Iain Whyte (PCA of SVP & Company Secretary) acquired 1,050 shares via dividend reinvestment at £19.6297.
- All transactions occurred on July 9, 2026 on the London Stock Exchange.
- Total aggregate value of all reported transactions is approximately £23,000 (based on ~1,170 shares at ~£19.63).
Financial Impact
Negligible, total transaction value ~£23,000 against a $106.9B market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006623 |
| Document: 0001654954-26-006623-index-headers.html | 0001654954-26-006623 |
| Document: 0001654954-26-006623-index.html | 0001654954-26-006623 |
| Document: 0001654954-26-006623.txt | 0001654954-26-006623 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers